Eliminating Hepatitis C Treatment Restrictions for DHCF Beneficiaries

July 22, 2020
Goal: Remove Restrictions to Hepatitis C Curative Treatment

• Eliminating hepatitis C in the District is a shared goal among DC Health and DHCF, and enabling access to curative treatment is a priority for achieving equitable outcomes for Medicaid beneficiaries.

• DC’s Medicaid program imposes variable restrictions across FFS and MCO programs for prescribing hepatitis C curative treatment:
  - Fibrosis score requirements
  - Abstinence requirements
  - Specialist requirements
  - Prior authorization

• Removal of fibrosis score restrictions is now financially feasible since pricing competition has drastically reduced the cost of hepatitis C curative treatment.
1. Eliminate minimum fibrosis score requirement across FFS and MCO programs – January 1, 2021
   • Currently working with actuary to ensure consideration of the change and impact to MCO rates.

2. Elimination of additional restrictions – for consideration for FY 2022:
   • Eliminate the abstinence requirement.
   • Eliminate the requirement that medications be prescribed by or in consultation with a specialist.
   • Eliminate prior authorization.